Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial

Published:2022-10 Issue:10 Volume:23 Page:1249-1260
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gu Weijie,Han Weiqing,Luo Hong,Zhou Fangjian,He Dalin,Ma Lulin,Guo Hongqian,Liang Chaozhao,Chong Tie,Jiang Jun,Chen Zhiwen,Wang Yong,Zou Qing,Tian Ye,Xiao Jun,Huang Jian,Zhu Shaoxing,Dong Qiang,Zhang Xiaoping,Li Hanzhong,Yang Xinfeng,Chen Chunxia,Li Junliang,Jin Chunlei,Zhang Xiaojing,Ye Dingwei

Funder

Jiangsu Hengrui Medicine

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival;Akaza;Cancer,2009

2. A re-assessment of the role of combined androgen blockade for advanced prostate cancer;Klotz;BJU Int,2004

3. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

4. Apalutamide for metastatic, castration-sensitive prostate cancer;Chi;N Engl J Med,2019

5. Enzalutamide with standard first-line therapy in metastatic prostate cancer;Davis;N Engl J Med,2019

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis;British Journal of Cancer;2024-09-02

2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer;European Urology;2024-08

3. Clinical efficacy of current treatments for high-volume metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis;Holistic Integrative Oncology;2024-07-22

4. Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer;BMJ Open;2024-07

5. Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis;Future Oncology;2024-06-19